RecruitingPhase 1NCT06543667
Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye
A Clinical Study for Safety and Efficacy Evaluation of Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye Syndrome
Sponsor
Iran University of Medical Sciences
Enrollment
30 participants
Start Date
Aug 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the safety and efficacy of Limbal Stem Cells derived Exosomes (LSC-Exo) in alleviation of dry eye symptoms
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Patients with complaints of burning or itching or feeling of a foreign body in the eye
- Moderate and severe dry eye severity
- Age between 18-70 years
Exclusion Criteria7
- Previous history of eye surgery
- Any disease that suppresses the immune system
- Pregnancy and breastfeeding
- Eyelid abnormalities
- Use of eye drops in the past year except artificial tears and lubricating ointments
- Use of systemic drugs that affect the tear film in last three months
- Use of contact lenses in the last three months
Interventions
BIOLOGICALLimbal Stem Cell Derived Exosomes Eye Drop
Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06543667